325 related articles for article (PubMed ID: 37455149)
1. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies.
Liu J; Di B; Xu LL
Cytokine Growth Factor Rev; 2023; 71-72():1-12. PubMed ID: 37455149
[TBL] [Abstract][Full Text] [Related]
2. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract][Full Text] [Related]
3. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
[TBL] [Abstract][Full Text] [Related]
4. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
Dharmani P; Chadee K
Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate).
Sattler L; Hanauer SB; Malter L
Curr Gastroenterol Rep; 2021 Dec; 23(12):30. PubMed ID: 34913108
[TBL] [Abstract][Full Text] [Related]
6. Treatment of inflammatory bowel disease (IBD).
Pithadia AB; Jain S
Pharmacol Rep; 2011; 63(3):629-42. PubMed ID: 21857074
[TBL] [Abstract][Full Text] [Related]
7. TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease.
Furfaro F; Alfarone L; Gilardi D; Correale C; Allocca M; Fiorino G; Argollo M; Zilli A; Zacharopoulou E; Loy L; Roda G; Danese S
Curr Drug Targets; 2021; 22(7):760-769. PubMed ID: 33475057
[TBL] [Abstract][Full Text] [Related]
8. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for the treatment of inflammatory bowel disease.
Wong U; Cross RK
Expert Opin Emerg Drugs; 2022 Dec; 27(4):369-377. PubMed ID: 36369862
[TBL] [Abstract][Full Text] [Related]
10. Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies.
Katsanos KH; Papamichael K; Feuerstein JD; Christodoulou DK; Cheifetz AS
Clin Immunol; 2019 Sep; 206():9-14. PubMed ID: 29545207
[TBL] [Abstract][Full Text] [Related]
11. Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.
Na SY; Kim YS
Korean J Intern Med; 2022 Sep; 37(5):906-919. PubMed ID: 35945034
[TBL] [Abstract][Full Text] [Related]
12. Review article: novel oral-targeted therapies in inflammatory bowel disease.
White JR; Phillips F; Monaghan T; Fateen W; Samuel S; Ghosh S; Moran GW
Aliment Pharmacol Ther; 2018 Jun; 47(12):1610-1622. PubMed ID: 29672874
[TBL] [Abstract][Full Text] [Related]
13. Study of tumor necrosis factor receptor in the inflammatory bowel disease.
Souza RF; Caetano MAF; Magalhães HIR; Castelucci P
World J Gastroenterol; 2023 May; 29(18):2733-2746. PubMed ID: 37274062
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response.
Elhag DA; Kumar M; Saadaoui M; Akobeng AK; Al-Mudahka F; Elawad M; Al Khodor S
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805965
[TBL] [Abstract][Full Text] [Related]
15. Review article: emerging drug therapies in inflammatory bowel disease.
Grossberg LB; Papamichael K; Cheifetz AS
Aliment Pharmacol Ther; 2022 Apr; 55(7):789-804. PubMed ID: 35166398
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
Catalan-Serra I; Brenna Ø
Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
[TBL] [Abstract][Full Text] [Related]
17. Current, New and Future Therapeutic Targets in Inflammatory Bowel Disease: A Systematic Review.
Alimohammadi N; Koosha F; Rafeian-Kopaei M
Curr Pharm Des; 2020; 26(22):2668-2675. PubMed ID: 32250220
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive therapies for inflammatory bowel disease.
Zenlea T; Peppercorn MA
World J Gastroenterol; 2014 Mar; 20(12):3146-52. PubMed ID: 24696600
[TBL] [Abstract][Full Text] [Related]
19. Phytochemicals and their potential usefulness in inflammatory bowel disease.
Somani SJ; Modi KP; Majumdar AS; Sadarani BN
Phytother Res; 2015 Mar; 29(3):339-50. PubMed ID: 25572840
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
